Conference Registration, Materials Pick- and Continental Breakfast in the Exhibit Hall

Coffee Break and Networking in the Exhibit Hall

Networking Lunch, Discussions with Exhibitors and View Posters

Tumor-Educated Platelets: A Biomarker Source for Molecular Cancer Diagnostics -- Platelet-based Liquid Biopsy
Bakhos A. Tannous, Associate Professor of Neurology, Massachusetts General Hospital and Harvard Medical School, United States of America

Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. In this presentation, we will discuss the potential use of TEPs for pan-cancer, multiclass cancer, and companion diagnostics, enabling clinical advances in blood-based "liquid biopsies".

Plasma Exosome Biomarkers of Immune Activation in HIV Patients on Antiretroviral Therapy
Dana Gabuzda, Professor of Neurology, Dana-Farber Cancer Institute and Harvard Medical School, United States of America

This presentation will discuss the analysis of plasma exosome protein and miRNA cargo from HIV patients with virological suppression on antiretroviral therapies and identification of exosome cargo correlating with clinical markers of immune activation.

Novel Approaches for Increasing Sensitivity and Specificity of Molecular Diagnostics Assays Following Mutation Enrichment
Mike Makrigiorgos, Professor, Dana-Farber Cancer Institute/Harvard Medical School, United States of America

Detecting rare mutations in clinical samples and liquid biopsies requires methods having highly increased sensitivity while retaining excellent specificity. We developed novel methods that provide mutation enrichment either prior to PCR or during PCR and enable established methodologies for detecting mutations at 0.1-0.01% levels or below. We present the advantages of combining a novel approach, NaME (Nuclease-assisted Mutation Enrichment) with COLD-PCR, digital PCR, high resolution melting or sequencing.

Coffee Break and Networking in the Exhibit Hall

DNA Sequencing of Clinical Plasma Samples to Identify Markers of Response and Resistance in Lung and Breast Cancer
Brian Dougherty, Executive Director, Translational Genomics, Oncology IMED, AstraZeneca R&D, United States of America

Clinical Utility and Deployment of CTCs
Mark Connelly, Chief Industrial Operations and R&D Officer, U.S., Menarini Silicon Biosystems, Inc., United States of America

Addressing the Challenges Confronting Molecular Tumor Profiling By Demonstrating Clinical Utility of ctDNA
John F. Beeler, Vice President, Business Development, Inivata Ltd., United Kingdom

Harnessing the potential of circulating cell-free tumour DNA (ctDNA) from blood as a source of a liquid biopsy is a “game-changer,” as it ushers in a new generation of molecular applications poised to impact the major aspects of a patient’s care including treatment stratification and response monitoring.   This liquid biopsy approach offers the opportunity to improve and/or resolve many of the limitations inherent in current molecular tumor profiling approaches  This presentation will address the current challenges associated with molecular tumor profiling and propose how these limitations can be overcome by employing a proprietary technology based on tagged-amplicon sequencing (TAm-Seq) to analyze ctDNA and address critical clinical decision points for enhance personalized medicine applications.

Networking Cocktail Reception for All Delegates, Speakers, Sponsors and Exhibitors

Close of Day 1 of the Conference. Extracellular Vesicles Dinner Short Course Begins.

Morning Coffee, Breakfast Pastries, and Networking

Single cell RNA-sequencing of Circulating Tumor Cells
David Ting, Assistant Professor Of Medicine, Harvard Medical School, United States of America

Circulating Tumor Cells (CTCs) are thought to be enriched for the precursors of metastasis.  The detection of CTCs has been shown to be a poor prognostic marker across a variety of malignancies.  However, the absolute number of CTCs found across technologies has revealed that CTC numbers do not necessarily correlate with tumor burden. This suggests that CTCs are heterogeneous and the complete metastatic program is not inherent to all CTCs.  To characterize the heterogeneity of CTCs, we have developed methods to perform large scale single cell RNA-sequencing of CTCs across malignancies.  In a pancreatic cancer mouse model we demonstrate that CTCs are heterogeneous and that not all CTCs are the same.  Together, our work suggests that the ability of CTCs to gain access to the vasculature is an early event in tumorigenesis and that characterizing the transcriptome of CTCs will not only provide novel predictive biomarkers, but also mechanistic insight into the metastatic cascade.

Standardizing Extracellular Small RNASeq for Biomarker Discovery
Yaoyu Wang, Associate Director, Dana-Farber Cancer Institute, United States of America

Extracellular small RNAs have recently come to attention as both biomarkers for disease states and functional regulators of cell-cell communication. While high-throughput sequencing (HTS) technology offers a potentially sensitive means to characterize and quantify these exRNAs, there is a lack of a systematic evaluation of the efficacy and reliability of HTS sequencing protocols to survey the extracellular RNA space. In this presentation, I will share our effort in establishing an extracellular RNA sequencing workflow for biomarker discovery.

Characterization of Extracellular Vesicles by RNA-Seq
Dima Ter-Ovanesyan, PhD Student/George Church and Aviv Regev Laboratories, Harvard University, United States of America

Extracellular vesicles are known to contain both coding and non-coding RNAs. We are using high-throughput sequencing (RNA-Seq) to characterize the full repertoire of RNAs in extracellular vesicles from different cell types.

Coffee Break and Networking in the Exhibit Hall

Computational Analysis of Exosomal Small-RNA-Seq Data
Robert Kitchen, Research Associate, Yale University, United States of America

Overview of analysis of small RNAs by RNA-sequencing, including best practices for mitigating nuisance contaminants and special considerations for profiling extra-cellular RNAs (exRNAs). Based on these best practices we present the extracellular RNA processing toolkit (exceRpt), a software suite for the analysis of RNA-seq data obtained from both cellular and extracellular small-RNA preparations. We extend beyond existing analysis methods used to assess cytosolic micro-RNAs (miRNAs) to specifically address experimental issues that may arise in exRNA profiling, such as variable contamination of ribosomal RNAs, the presence of other smallRNA biotypes, and fragmented mRNA and long non-coding RNA transcripts.  We also discuss alignments to exogenous miRNAs in miRBase, as well as to exogenous ribosomal RNAs in RDP for comparison with studies of the microbiome.

Exploring the Intersection of Precision Medicine and Population Health: Avoiding a Zero Sum Game
Laura Housman, Global Head, Pharmaceutical Business; Senior Vice President, Corporate Development, Molecular Health, United States of America

Precision/personalized medicine is clearly having its moment in the sun.  From publications to funding the emphasis on targeted therapies as well as gene-based testing and biomarker discoveries has been extensive and expanding. However, little has changed in the understanding of underlying disease- its etiology, prevention and management. Are there ways to harness the power and promise of precision medicine in support of population health goals?  Can “precision health management” become the next new thing?

The Patent Landscape of Precision Medicine in the USA: How Recent Court Decisions Will Affect this Rapidly Growing Field
Jorge Goldstein, Senior Director, Sterne Kessler Goldstein and Fox PLLC, United States of America

There have been dramatic legal changes in the USA on the patent eligibility of natural correlations (where a patent claim is drawn to a genetic diagnostic method of determining propensity to disease) and on the concept of "split infringement" (where two different parties, such as a clinical lab and a physician, each carry out one of a two-step patented process, such as detecting a mutation and then administering a personalized drug). These legal changes  have led to severe  problems with the patent protection and enforcement of precision medicine methods. We will discuss these legal developments and propose solutions.

Networking Lunch, Discussions with Exhibitors and View Posters